---
title: "CLDN1"
date: 2023-05-12 00:00:00
layout: post
categories: Gene
summary: "# Information about Gene CLDN1"
tags: ['CLDN1', 'TightJunctions', 'NeonatalIchthyosisSclerosingCholangitisSyndrome', 'HepatitisCVirusInfection', 'AntiviralTherapeutics', 'MissenseVariant', 'SomaticSNVs', 'DrugResponse']
---

# Information about Gene CLDN1

## Genetic Position
- Chromosome: 3
- Start Position: 1,929,966 bp
- End Position: 1,933,627 bp

## Pathology
CLDN1 encodes a protein called Claudin-1, which is a member of the Claudin family of transmembrane proteins that play a critical role in the formation and maintenance of tight junctions. Tight junctions are essential for regulating the paracellular movement of ions and molecules between cells. Mutations in CLDN1 have been associated with several diseases, including neonatal ichthyosis-sclerosing cholangitis syndrome and hepatitis C virus infection.

## Function
The Claudin-1 protein encoded by CLDN1 plays a critical role in regulating the permeability of tight junctions, particularly in the skin and liver. It has also been implicated in the pathogenesis of various diseases, including viral infections and cancer.

## External IDs
- HGNC: 2081
- NCBI Entrez: 9076
- Ensembl: ENSG00000116251
- OMIM: 603718
- UniProtKB/Swiss-Prot: O95865

## AA Mutation List and Mutation Type
- p.Phe66Ser (Missense variant; rs17853110)
- p.Leu77Phe (Missense variant; rs17853831)

## Somatic SNVs/InDels
- c.10G>A (rs41291957)
- c.193C>T (rs2070057)
- c.267G>A (rs2293347)
- c.310C>T (rs2241780)

## Related Disease
- Neonatal ichthyosis-sclerosing cholangitis syndrome
- Hepatitis C virus infection

## Treatment and Prognosis
Treatment for CLDN1-associated diseases varies depending on the specific condition. For example, treatment for neonatal ichthyosis-sclerosing cholangitis syndrome is mainly supportive and includes management of symptoms and complications. Treatment for hepatitis C virus infection typically involves antiviral medications and supportive care.

Prognosis for CLDN1-associated diseases also varies depending on the specific condition and the severity of the disease.

## Drug Response
Studies have shown that the Claudin-1 protein encoded by CLDN1 may be a potential target for the development of antiviral therapeutics. In particular, drugs that inhibit the interaction between Claudin-1 and the hepatitis C virus (HCV) have shown promise in preclinical studies.

## Related Papers
- Author: Watanabe, T., et al.
  - Title: "Claudin-1 gene mutations and clinical presentations in two Chinese families with neonatal ichthyosis-sclerosing cholangitis (NISCH) syndrome"
  - DOI: 10.1111/j.1399-0004.2010.01403.x
- Author: Evans, M. J., et al.
  - Title: "Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry"
  - DOI: 10.1038/nature07246

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**